K/DOQI.Clinical practices guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis2003; 42(Suppl 3): S12–28.
2.
ChertowG.M., BurkeS.K., LazarusM., StenzelK.H., WomboltD., GoldbergD.Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.Am J Kidney Dis1997; 29: 66–71.
3.
KatopodisK.P., AndrikosE.K., GouvaC.D., BairaktariE.T., NikolopoulosP.M., TakouliL.K.Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.Perit Dial Int2006; 26: 320–7.
4.
HuW.H.C., LamK.F., WongY.H., LamC.L., HuiW.M., LaiK.C.The Hong Kong Index of Dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia.J Gastroenterol Hepatol2002; 17: 545–51.
IwasakiY., TakamiH., TaniM., YamaguchiY., GotoH., GotoY.Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.Ther Apher Dial2005; 9: 347–51.
7.
AlmirallJ., LopezT., VallveM., RuizA., LibreJ., BetriuA.Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphatemia of haemodialysis patients.Nephron2004; 97: c17–22.
8.
McIntyreC.W., PatelV., TaylorG.S., FluckR.A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients.Nephrol Dial Transplant2002; 17: 1643–8.
9.
Cher towG.M., BurkeS.K., DillonM.A., SlatopolskyE.Long term effects of sevelamer hydrochloride as the calcium x phosphate product and lipid profile of haemodialysis patients.Nephrol Dial Transplant1999; 14: 2907–14.
